logo
Hey, Hospitalists, Those Hoofbeats Sometimes May Be a Zebra

Hey, Hospitalists, Those Hoofbeats Sometimes May Be a Zebra

Medscape15-05-2025
Kelly Chellis could have dismissed the random swollen knee on her then-6-year-old, Trys. At that age, children get injured all the time, and Trys could have tripped, twisted it on the playground, or done one of many other things and simply forgotten to mention it.
While Trys's swollen knee at first seemed to fall under the category of typical childhood bumps and bruises, the journey that followed is an important example of the need for hospitalists to stay curious and keep an open mind in patient diagnosis.
'The week of Trys's sixth birthday, they woke up one morning with their right knee swollen to the size of a softball,' Chellis recalled. 'We kept saying, 'Does it hurt?' but Trys really wanted to just go on to school.'
Kelly Chellis
Chellis' instincts, fine-tuned where Trys was concerned, given that the child had survived a congenital heart defect, gave her pause, though. She took Trys to their regular pediatrician, where x-rays were taken. Although the films showed nothing irregular, the pediatrician had them proceed to Nationwide Children's Hospital in Columbus, Ohio.
'We were put on the infectious disease floor because they thought that there was an infection in the kneecap, and they were just (administering) IV [intravenous] antibiotics,' Chellis recalled, saying that all of the tests that the epidemiologists ran came back normal. Protocols on the floor restricted their movements in case Trys had something communicable. As Chellis kept them occupied inside their room, a break in the case emerged from a strangely timed art project.
'Out of the blue, [Trys] wanted to draw a hand turkey. In March, that's kind of odd — to want to draw a turkey,' Chellis said. 'But I'm like, great, I'll trace your hand. Then when Trys laid their hand down on the table, their fingers would not actually lay flat.'
Chellis immediately drew the care team's attention to Trys's hand, which led to the hospital's rheumatology team joining the case. Shortly thereafter, Trys was diagnosed with juvenile idiopathic arthritis (JIA). Chellis was stunned, but they finally had an answer.
Don't Let the Obvious Block the Possible
Occam's Razor, often attributed to 14th-century friar William of Ockham, said that if you have two competing ideas to explain the same phenomenon, you should prefer the simpler one. A frequently used, more colloquial explanation of the principle is 'When you hear hoofbeats, look for horses, not zebras.'
While Occam's razor is helpful in many situations, it has a caveat: Zebras still exist, especially in the medical field. Trying to find the balance between relying on medical training, which is based on pattern recognition and hard data, and the potential for a variety of diseases, like JIA in Trys's case, to manifest on the diagnostic spectrum can be difficult, especially for doctors just entering the field.
Rebecca Carter, MD
'In any diagnosis, I try to consider the two extremes: One, what is most likely, and two, what would be most dangerous to miss,' said Rebecca Carter, MD, associate professor of pediatrics and division head of General Pediatrics at the University of Maryland School of Medicine, Baltimore. 'While much of what we do in medicine, and certainly most of what I do in general pediatrics, comes down to the notion that common things are common, our most significant impact, and the true foundation of our training, comes down to not missing the rare or less common presentations.'
While there are many such diseases that affect all ages, JIA is a textbook example of a diagnostic outlier in many ways: First, as profiled in Trys's case, the symptoms of JIA — a group of disorders in which the immune system mistakenly targets the body's own joints and tissues, triggering widespread inflammation — can overlap with more common conditions like sports injuries or infections.
Many other early symptoms compiled by the Arthritis Foundation , like morning stiffness and mild fever, are nonspecific, and symptoms come and go and can be anywhere from mild to excruciatingly painful and disabling during attacks.
All of these factors make JIA diagnostically elusive, even though it is the most common form of arthritis in young people, affecting about 300,000 children in the United States, according to statistics from the Arthritis Foundation. As a result, the American College of Rheumatology reported that some children wait months, even years, for a diagnosis.
'JIA is a challenge to diagnose, particularly because most kids just compensate for any joint issues they could possibly have by limping or just making up for it in any way that helps them keep going,' said Aixa Toledo-Garcia, RhMSUS, and managing partner at The Center for Rheumatology in Albany, New York. Toledo-Garcia is not affiliated with Trys's case but said the pattern of their diagnosis is very common. 'It's usually the parent that notices the limp or the swollen joint.
Practical Care and Uncommon Diagnoses: Maintaining a Balance
Carter said that longtime pattern recognition experience in a clinical setting is what alerts doctors to medical outliers like JIA.
'As physicians, we have to see hundreds or even thousands of cases of the same common illness in order to detect when something feels off or different about the patient in front of us,' she said. 'All those hours of medical school and residency give us this perspective, to help us to fully trust our gut when there is something uncommon about how a child presents, and to know when to dive a bit deeper to explore alternative diagnoses to make sure we get it right.'
'Yet' is a great addition to carrying out the process of diagnosis, added Dympna Weil, MD, a board-certified obstetrician/gynecologist and master coach at Prescribing Possibility in Upstate New York.
'By this, I mean, we must use those skills we learn and continue to hone with time. We need to let go of any ego we have and embrace the fact that we don't and cannot possibly know everything,' Weil said. 'Sometimes, patients' bodies don't read the textbooks. They may present differently than the books would tell us they 'should.' So admitting we aren't sure exactly what is going on yet can go a long way in keeping our minds open to other diagnostic possibilities.'
If the patient doesn't improve after being given the standard treatment for the diagnosis reached, Weil said clinicians should stay open to the possibility that perhaps the initial diagnosis was incorrect.
'We may need to go back to the history and listen again to the patient's presentation or reassess their physical exam to better inform us. It is critical to confidently know what you know, but equally, to know what you don't know and to not be afraid to ask for a consult or pursue a different path.'
Trys's diagnosis of JIA, while shocking, brought clarity. It shifted the family's focus toward proactive care, which included immunosuppressive medications to reduce inflammation and slow disease progression. Since then, both Chellis and her child have become advocates for JIA and participants in the fight for better healthcare policies both statewide and nationally. Partially as a result of their experience, Trys is now studying for their Medical College Admission Tests, and their medical career will clearly be informed by how their diagnosis and subsequent treatment played out.
Standing Out in the Herd
Medical training emphasizes pattern recognition and probability for a reason: You don't have time to agonize over each and every one of the thousands of possibilities that the rash on the patient in bed 5 might indicate. However, there are times that the most meaningful diagnoses come from the smallest observations, the details that might otherwise seem inconsequential.
More than anything else, the fact that a child's random idea to draw a hand turkey in the middle of March ended up being a critically important key to diagnosis highlights the fact that curiosity is an essential tool in medicine, right alongside the stethoscope. You may even have to fight a few people on this, but sometimes, when you hear hoofbeats, they don't belong to a horse. Sometimes, they really do belong to a zebra.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Interferon-Driven Genes Signal Methotrexate Response in JIA
Interferon-Driven Genes Signal Methotrexate Response in JIA

Medscape

time25-06-2025

  • Medscape

Interferon-Driven Genes Signal Methotrexate Response in JIA

TOPLINE: Higher baseline expression of interferon (IFN)-driven genes was tied to a better response to methotrexate in patients with juvenile idiopathic arthritis. METHODOLOGY: Analysis of the link between blood biomarkers and response to methotrexate in 97 children (median age at baseline, 8.5 years; 62.9% women) with nonsystemic juvenile idiopathic arthritis (JIA). RNA sequencing was used to understand gene expression on CD4 + , CD8 + , CD14 + , and CD19 + cells and total peripheral blood mononuclear cells at baseline and at 6 months post-treatment with methotrexate. , CD8 , CD14 , and CD19 cells and total peripheral blood mononuclear cells at baseline and at 6 months post-treatment with methotrexate. The link between response to methotrexate therapy and gene activity in specific cell types was tested using the limma-voom, gene set enrichment analysis, and a new 51-gene score. Results were validated in 73 children with JIA, and pretreatment gene expression data were used to compare results with 240 adult patients with rheumatoid arthritis (RA). TAKEAWAY: Gene enrichment in the IFN-alpha (type I) and IFN-gamma (type II) response pathways was linked with treatment response in many cell types isolated from children with nonsystemic JIA. Higher baseline expression of both type I and type II IFN-driven genes was associated with a better response to methotrexate at 6 months post-treatment in JIA patients but not in adult RA patients. The 51-gene score, calculated from the expression levels of 51 specific IFN-response genes, was significantly higher in patients who responded to methotrexate than in those who did not (P = .00556). IN PRACTICE: 'It is possible that MTX [methotrexate] treatment is more effective in a distinct immunophenotype present across many International League of Associations for Rheumatology subtypes, where IFN-driven processes are dominant early in the disease,' the authors wrote. 'Our study provides proof of principle that carefully designed analyses can yield hope for a more precision-based approach to treatment in the future for children and families living with arthritis,' they added. SOURCE: This study was led by Melissa Kartawinata of University College London Great Ormond Street Institute of Child Health in London and Wei-Yu Lin of the University of Cambridge in Cambridge, both in England. It was published online on May 20, 2025, in Annals of the Rheumatic Diseases. LIMITATIONS: This study may have been underpowered to identify pathways with small but biologically significant influence on treatment response. Whole-blood RNA samples were unavailable to test the association between 51-IFN gene score and treatment response. Additionally, treatment response can fluctuate over time, and this study only analyzed outcomes at 6 months. DISCLOSURES: This study received support from the Medical Research Council, Versus Arthritis, Great Ormond Street Hospital Children's Charity, and Olivia's Vision. Additional support was provided by multiple organizations, including the Wellcome Trust and other sources. Several authors reported receiving funds and contributions in kind from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Hey, Hospitalists, Those Hoofbeats Sometimes May Be a Zebra
Hey, Hospitalists, Those Hoofbeats Sometimes May Be a Zebra

Medscape

time15-05-2025

  • Medscape

Hey, Hospitalists, Those Hoofbeats Sometimes May Be a Zebra

Kelly Chellis could have dismissed the random swollen knee on her then-6-year-old, Trys. At that age, children get injured all the time, and Trys could have tripped, twisted it on the playground, or done one of many other things and simply forgotten to mention it. While Trys's swollen knee at first seemed to fall under the category of typical childhood bumps and bruises, the journey that followed is an important example of the need for hospitalists to stay curious and keep an open mind in patient diagnosis. 'The week of Trys's sixth birthday, they woke up one morning with their right knee swollen to the size of a softball,' Chellis recalled. 'We kept saying, 'Does it hurt?' but Trys really wanted to just go on to school.' Kelly Chellis Chellis' instincts, fine-tuned where Trys was concerned, given that the child had survived a congenital heart defect, gave her pause, though. She took Trys to their regular pediatrician, where x-rays were taken. Although the films showed nothing irregular, the pediatrician had them proceed to Nationwide Children's Hospital in Columbus, Ohio. 'We were put on the infectious disease floor because they thought that there was an infection in the kneecap, and they were just (administering) IV [intravenous] antibiotics,' Chellis recalled, saying that all of the tests that the epidemiologists ran came back normal. Protocols on the floor restricted their movements in case Trys had something communicable. As Chellis kept them occupied inside their room, a break in the case emerged from a strangely timed art project. 'Out of the blue, [Trys] wanted to draw a hand turkey. In March, that's kind of odd — to want to draw a turkey,' Chellis said. 'But I'm like, great, I'll trace your hand. Then when Trys laid their hand down on the table, their fingers would not actually lay flat.' Chellis immediately drew the care team's attention to Trys's hand, which led to the hospital's rheumatology team joining the case. Shortly thereafter, Trys was diagnosed with juvenile idiopathic arthritis (JIA). Chellis was stunned, but they finally had an answer. Don't Let the Obvious Block the Possible Occam's Razor, often attributed to 14th-century friar William of Ockham, said that if you have two competing ideas to explain the same phenomenon, you should prefer the simpler one. A frequently used, more colloquial explanation of the principle is 'When you hear hoofbeats, look for horses, not zebras.' While Occam's razor is helpful in many situations, it has a caveat: Zebras still exist, especially in the medical field. Trying to find the balance between relying on medical training, which is based on pattern recognition and hard data, and the potential for a variety of diseases, like JIA in Trys's case, to manifest on the diagnostic spectrum can be difficult, especially for doctors just entering the field. Rebecca Carter, MD 'In any diagnosis, I try to consider the two extremes: One, what is most likely, and two, what would be most dangerous to miss,' said Rebecca Carter, MD, associate professor of pediatrics and division head of General Pediatrics at the University of Maryland School of Medicine, Baltimore. 'While much of what we do in medicine, and certainly most of what I do in general pediatrics, comes down to the notion that common things are common, our most significant impact, and the true foundation of our training, comes down to not missing the rare or less common presentations.' While there are many such diseases that affect all ages, JIA is a textbook example of a diagnostic outlier in many ways: First, as profiled in Trys's case, the symptoms of JIA — a group of disorders in which the immune system mistakenly targets the body's own joints and tissues, triggering widespread inflammation — can overlap with more common conditions like sports injuries or infections. Many other early symptoms compiled by the Arthritis Foundation , like morning stiffness and mild fever, are nonspecific, and symptoms come and go and can be anywhere from mild to excruciatingly painful and disabling during attacks. All of these factors make JIA diagnostically elusive, even though it is the most common form of arthritis in young people, affecting about 300,000 children in the United States, according to statistics from the Arthritis Foundation. As a result, the American College of Rheumatology reported that some children wait months, even years, for a diagnosis. 'JIA is a challenge to diagnose, particularly because most kids just compensate for any joint issues they could possibly have by limping or just making up for it in any way that helps them keep going,' said Aixa Toledo-Garcia, RhMSUS, and managing partner at The Center for Rheumatology in Albany, New York. Toledo-Garcia is not affiliated with Trys's case but said the pattern of their diagnosis is very common. 'It's usually the parent that notices the limp or the swollen joint. Practical Care and Uncommon Diagnoses: Maintaining a Balance Carter said that longtime pattern recognition experience in a clinical setting is what alerts doctors to medical outliers like JIA. 'As physicians, we have to see hundreds or even thousands of cases of the same common illness in order to detect when something feels off or different about the patient in front of us,' she said. 'All those hours of medical school and residency give us this perspective, to help us to fully trust our gut when there is something uncommon about how a child presents, and to know when to dive a bit deeper to explore alternative diagnoses to make sure we get it right.' 'Yet' is a great addition to carrying out the process of diagnosis, added Dympna Weil, MD, a board-certified obstetrician/gynecologist and master coach at Prescribing Possibility in Upstate New York. 'By this, I mean, we must use those skills we learn and continue to hone with time. We need to let go of any ego we have and embrace the fact that we don't and cannot possibly know everything,' Weil said. 'Sometimes, patients' bodies don't read the textbooks. They may present differently than the books would tell us they 'should.' So admitting we aren't sure exactly what is going on yet can go a long way in keeping our minds open to other diagnostic possibilities.' If the patient doesn't improve after being given the standard treatment for the diagnosis reached, Weil said clinicians should stay open to the possibility that perhaps the initial diagnosis was incorrect. 'We may need to go back to the history and listen again to the patient's presentation or reassess their physical exam to better inform us. It is critical to confidently know what you know, but equally, to know what you don't know and to not be afraid to ask for a consult or pursue a different path.' Trys's diagnosis of JIA, while shocking, brought clarity. It shifted the family's focus toward proactive care, which included immunosuppressive medications to reduce inflammation and slow disease progression. Since then, both Chellis and her child have become advocates for JIA and participants in the fight for better healthcare policies both statewide and nationally. Partially as a result of their experience, Trys is now studying for their Medical College Admission Tests, and their medical career will clearly be informed by how their diagnosis and subsequent treatment played out. Standing Out in the Herd Medical training emphasizes pattern recognition and probability for a reason: You don't have time to agonize over each and every one of the thousands of possibilities that the rash on the patient in bed 5 might indicate. However, there are times that the most meaningful diagnoses come from the smallest observations, the details that might otherwise seem inconsequential. More than anything else, the fact that a child's random idea to draw a hand turkey in the middle of March ended up being a critically important key to diagnosis highlights the fact that curiosity is an essential tool in medicine, right alongside the stethoscope. You may even have to fight a few people on this, but sometimes, when you hear hoofbeats, they don't belong to a horse. Sometimes, they really do belong to a zebra.

GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer

Yahoo

time03-01-2025

  • Yahoo

GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer

SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment of Jie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of strategic leadership experience within the biopharmaceutical and healthcare industries, especially in managing complex projects, establishing new business operations, optimizing processes, and guiding critical decision-making initiatives. Prior to joining GRIT Bio as Chief Operating Officer, Dr. Jia served as a senior executive at CARsgen Therapeutics, where he successfully transformed the company from a startup to a public entity by establishing and spearheading U.S. operations. Before transitioning into the industry, Dr. Jia was an assistant professor at the Cleveland Clinic and Case Western Reserve University. Dr. Jia holds a Bachelor of Science in Biochemistry from Sichuan University, a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, a Postdoctoral Fellow Certificate in Molecular Medicine from the Cleveland Clinic, and an MBA in Leadership and Digital Marketing from Youngstown State University. "We are delighted to welcome Dr. Jia as GRIT Bio's Chief Operating Officer," said Dr. Liu, Yarong, Chairman and CEO of GRIT Bio, "His experience in leading biotech companies and developing markets and collaborations overseas aligns seamlessly with GRIT Bio's international vision. We are confident that Dr. Jia's leadership and professional expertise will accelerate our global mission of developing breakthrough cell therapies for solid tumor patients." Dr. Jia commented, "I am honored to join GRIT Bio and collaborate with the team. With outstanding scientists and proprietary cell therapy platforms, GRIT Bio has generated multiple differentiated TIL projects that have tremendous potentials, and maintained leading positions in development globally. I look forward to advancing development and collaborations involving the technologies and projects and contributing to the future success of the company." About GRIT Bio GRIT Bio was founded in 2019 as an innovative biopharmaceutical company, focused on immune cell treatments for oncology and characterized by a R&D pipeline in TIL therapies. GRIT Bio has completed multiple rounds of equity financing and is backed by renowned venture capital funds. GT101, a proprietary injectable developed by GRIT Bio, is the first TIL therapy that entered registrational clinical trial. GT 101 is currently in pivotal Phase II clinical study. GRIT Bio's GT201 injectable, the first TIL therapy with membrane-bound IL-15 complex, has cleared IND in both US and China. Core R&D platforms of the company include StemTexp® stemness TIL expansion platform, StaViral® stably virus transfected cell lines, ImmuT Finder® immune modulator target discovery platform, and KOReTIL® high-efficiency gene knock-out system. Based on the platforms, GRIT Bio generated a series of next-generation gene-edited TIL therapies. With internationally advanced technology reserve and industry resources, GRIT Bio aims to develop breakthrough cell therapies for solid tumors and bring new hope to cancer patients. For further information, please visit: Investor ContactYuan Wang+86-21- Media ContactRong Peng+86-21- 50828029PR@ View original content to download multimedia: SOURCE Grit Biotechnology Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store